<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00288470</url>
  </required_header>
  <id_info>
    <org_study_id>HYLA-001-01</org_study_id>
    <nct_id>NCT00288470</nct_id>
  </id_info>
  <brief_title>A Double-blinded Evaluation of Safety and Efficacy of Hylaform and Hylaform Plus Compared to Zyplast.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      A clinical study to investigate the safety and efficacy of Hylaform and Hylaform Plus for
      correction of facial wrinkles.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date>August 2003</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority as compared to standard of care as assigned by blinded reviewer.</measure>
  </primary_outcome>
  <condition>Facial Wrinkles</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hylaform, Hylaform Plus (hylan B gel)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  bilateral nasolabial folds with severity score 3 or 4 on the 6-point grading scale

        Exclusion Criteria:

          -  pregnant/lactating women

          -  patients who previously received permanent facial implants or using ovet-the-counter
             products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>February 7, 2006</study_first_submitted>
  <study_first_submitted_qc>February 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2006</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Genzyme Corporation</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

